Hong Kong vs Mus: HIV-positive TB patients on ART (antiretroviral therapy)
Hong Kong
100.0%
in 2024
Mus
100.0%
in 2024
Hong Kong rank
1st
Mus rank
1st
HIV-positive TB patients on ART (antiretroviral therapy) over time
- Hong Kong
- Mus
How they compare
Hong Kong currently reports 100.0% against 100.0% in Mus, a difference of 0.0%.
The two have swapped places 3 times across 18 shared years of data; in 2003 it was Hong Kong ahead.
Hong Kong ranks 1st and Mus ranks 1st of 144 countries.
Mus has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Hong Kong | Mus | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 53.4% | 72.0% | 18.6% | Mus |
| 2010s | 31.1% | 85.0% | 53.9% | Mus |
| 2020s | 92.2% | 100.0% | 7.8% | Mus |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv-positive tb patients on art (antiretroviral therapy), Hong Kong or Mus?
- Hong Kong, at 100.0% against 100.0% in Mus as of 2024.
- What is the difference in hiv-positive tb patients on art (antiretroviral therapy) between Hong Kong and Mus?
- 0.0%, with Hong Kong ahead.
- How many years of comparable data are there for Hong Kong and Mus?
- 18 years are reported by both, from 2003 to 2024.
- How do Hong Kong and Mus rank globally for hiv-positive tb patients on art (antiretroviral therapy)?
- Hong Kong ranks 1st and Mus ranks 1st of 144 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as HIV-positive TB patients on ART (antiretroviral therapy) (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.